Evidence labels explain what kind of source is being read.
Dictionary / Evidence method
Mechanistic evidence
Evidence about plausible biological pathways, not proof of consumer benefit.
Evidence methodterm category
8related public pages
editorial navigationdefinition status
draftreview status
382exact evidence rows
325exact source links
1052nearby evidence rows
739nearby source links
1do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
Mechanistic evidence explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
325 direct sources linked to approved workbench claims. PubMed 39528623
1052 nearby evidence rows and 739 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
Mechanistic evidence is used in this encyclopedia as a evidence method term. Evidence about plausible biological pathways, not proof of consumer benefit.
Evidence-method terms describe how a source should be read. They help separate human trials, observational work, preclinical work, mechanistic studies, and explicit evidence gaps.
Also searched as: biochemical, mechanism, mechanistic, pharmacological.
Do not confuse with:
Evidence Guardrail
How to read it without overreaching
Use this term to classify the kind of evidence, not to inflate it. A stronger-sounding label still needs source details, study context, outcome measures, and limits.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 39528623
Distinct source records under those exact rows. PubMed 39528623
Source-backed public pages where this vocabulary is likely useful. Open related page
Evidence rows available on those related public pages. Open related page
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 39528623
- Open related pages.Use nearby pages for broader source-backed context. Related page
- Keep the boundary.A method label describes evidence type; it does not make the evidence stronger.
Exact Evidence Rows
Approved source-backed rows linked to this term
382 exact rows
No matching evidence rows.
Evidence Group
Mechanistic or Pharmacological
382 exact rows / 325 sources
Evidence row 13 / evidence context
CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats.
mechanistic or pharmacological / low confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Evidence class is mechanistic or pharmacological.
Evidence row 35 / evidence context
CBC studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PubMed 41680865
Evidence class is mechanistic or pharmacological.
Evidence row 44 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
mechanistic or pharmacological / very_low confidence.
Cannabis Therapeutics and the Future of Neurology. PubMed 30405366
Evidence class is mechanistic or pharmacological.
Evidence row 47 / evidence context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
mechanistic or pharmacological / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Evidence class is mechanistic or pharmacological.
Evidence row 74 / evidence context
CBC studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PubMed 37764262
Evidence class is mechanistic or pharmacological.
Evidence row 75 / evidence context
CBC studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation. PubMed 41256665
Evidence class is mechanistic or pharmacological.
Evidence row 76 / evidence context
CBC studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation. PubMed 42139799
Evidence class is mechanistic or pharmacological.
Evidence row 77 / evidence context
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PubMed 27573936
Evidence class is mechanistic or pharmacological.
Evidence row 79 / evidence context
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. PubMed 42196303
Evidence class is mechanistic or pharmacological.
Evidence row 80 / evidence context
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PubMed 33230154
Evidence class is mechanistic or pharmacological.
Evidence row 81 / evidence context
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips. PubMed 39968488
Evidence class is mechanistic or pharmacological.
Evidence row 82 / evidence context
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
The Impact of Major and Minor Phytocannabinoids on the Maintenance and Function of INS-1 β-Cells Under High-Glucose and High-Lipid Conditions. PubMed 40363798
Evidence class is mechanistic or pharmacological.
Evidence row 88 / evidence context
THCA studied for THCA-specific safety, effect, or mechanism claims.
mechanistic or pharmacological / very_low confidence.
Plasma cannabinoid concentrations and transference during long-term industrial hemp administration in cattle. PubMed 41358942
Evidence class is mechanistic or pharmacological.
Evidence row 103 / evidence context
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
mechanistic or pharmacological / very_low confidence.
Effects of maternal edible THC consumption on offspring lung growth and function in a rhesus macaque model. PubMed 39903192
Evidence class is mechanistic or pharmacological.
Evidence row 118 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabidivarin is anticonvulsant in mouse and rat. PubMed 22970845
Evidence class is mechanistic or pharmacological.
Evidence row 119 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. PubMed 31447649
Evidence class is mechanistic or pharmacological.
Evidence row 121 / evidence context
CBDV studied for Seizure and neurodevelopmental outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans. PubMed 36583706
Evidence class is mechanistic or pharmacological.
Evidence row 127 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. PubMed 29057454
Evidence class is mechanistic or pharmacological.
Evidence row 129 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. PubMed 32488349
Evidence class is mechanistic or pharmacological.
Evidence row 130 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats. PubMed 31897571
Evidence class is mechanistic or pharmacological.
Evidence row 131 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. PubMed 23121618
Evidence class is mechanistic or pharmacological.
Evidence row 133 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. PubMed 24595502
Evidence class is mechanistic or pharmacological.
Evidence row 137 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Antiviral activities of hemp cannabinoids. PubMed 37083031
Evidence class is mechanistic or pharmacological.
Evidence row 138 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. PubMed 30225659
Evidence class is mechanistic or pharmacological.
Evidence row 143 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
The effect of phytocannabinoids on airway hyper-responsiveness, airway inflammation, and cough. PubMed 25655949
Evidence class is mechanistic or pharmacological.
Evidence row 146 / evidence context
CBDA studied for nausea-related or inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Behavioural and molecular effects of cannabidiolic acid in mice. PubMed 32798553
Evidence class is mechanistic or pharmacological.
Evidence row 157 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. PubMed 39596290
Evidence class is mechanistic or pharmacological.
Evidence row 161 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PubMed 42163693
Evidence class is mechanistic or pharmacological.
Evidence row 164 / evidence context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. PubMed 39004335
Evidence class is mechanistic or pharmacological.
Evidence row 165 / evidence context
CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. PubMed 41822224
Evidence class is mechanistic or pharmacological.
Evidence row 202 / evidence context
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics.
mechanistic or pharmacological / very_low confidence.
Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα. PubMed 31325449
Evidence class is mechanistic or pharmacological.
Evidence row 207 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Oxa-adamantyl cannabinoids. PubMed 33636308
Evidence class is mechanistic or pharmacological.
Evidence row 216 / evidence context
THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
mechanistic or pharmacological / very_low confidence.
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PubMed 27498155
Evidence class is mechanistic or pharmacological.
Evidence row 224 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. PubMed 25999668
Evidence class is mechanistic or pharmacological.
Evidence row 225 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
mechanistic or pharmacological / very_low confidence.
Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology. PubMed 37458709
Evidence class is mechanistic or pharmacological.
Evidence row 243 / evidence context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic investigations. PubMed 42106886
Evidence class is mechanistic or pharmacological.
Evidence row 254 / evidence context
CBD modulates receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. PubMed 23924692
Evidence class is mechanistic or pharmacological.
Evidence row 257 / evidence context
CBD modulates receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets. PubMed 40432283
Evidence class is mechanistic or pharmacological.
Evidence row 260 / evidence context
Endocannabinoids modulates receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. PubMed 18755158
Evidence class is mechanistic or pharmacological.
Evidence row 262 / evidence context
Endocannabinoids modulates receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids. PubMed 16107637
Evidence class is mechanistic or pharmacological.
Evidence row 263 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Mu Opioid Receptors Acutely Regulate Adenosine Signaling in Striatal Glutamate Afferents. PubMed 35091505
Evidence class is mechanistic or pharmacological.
Evidence row 267 / evidence context
Cannabinoids modulates receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Activation of nicotinic receptors on GABAergic amacrine cells in the rabbit retina indirectly stimulates dopamine release. PubMed 11347816
Evidence class is mechanistic or pharmacological.
Evidence row 268 / evidence context
Endocannabinoids studied for Cannabinoids and immune modulation research outcomes.
mechanistic or pharmacological / very_low confidence.
Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations. PubMed 40016352
Evidence class is mechanistic or pharmacological.
Evidence row 270 / evidence context
PEA studied for Cannabinoids and immune modulation research outcomes.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. PubMed 35176443
Evidence class is mechanistic or pharmacological.
Evidence row 271 / evidence context
Endocannabinoids studied for Cannabinoids and immune modulation research outcomes.
mechanistic or pharmacological / very_low confidence.
Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells. PubMed 34607960
Evidence class is mechanistic or pharmacological.
Evidence row 272 / evidence context
Endocannabinoids studied for Cannabinoids and immune modulation research outcomes.
mechanistic or pharmacological / very_low confidence.
Impact of Chronic Moderate Exercise on Immune Cells and Cytokine Levels in Rats: Focus on the Endocannabinergic Pathway. PubMed 37962860
Evidence class is mechanistic or pharmacological.
Evidence row 274 / evidence context
Cannabinoids studied for Cannabinoids and immune modulation research outcomes.
mechanistic or pharmacological / very_low confidence.
Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy. PubMed 39334169
Evidence class is mechanistic or pharmacological.
Evidence row 277 / evidence context
THC studied for receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Antiviral activities of hemp cannabinoids. PubMed 37083031
Evidence class is mechanistic or pharmacological.
Evidence row 278 / evidence context
THC studied for receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain. PubMed 38162115
Evidence class is mechanistic or pharmacological.
Evidence row 279 / evidence context
CBD studied for receptor, target, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. PubMed 34980287
Evidence class is mechanistic or pharmacological.
Evidence row 292 / evidence context
CBD studied for Endocannabinoids and endocannabinoid-like lipids research topics.
mechanistic or pharmacological / very_low confidence.
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. PubMed 17965195
Evidence class is mechanistic or pharmacological.
Evidence row 301 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
mechanistic or pharmacological / very_low confidence.
Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. PubMed 40269679
Evidence class is mechanistic or pharmacological.
Evidence row 305 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
mechanistic or pharmacological / very_low confidence.
Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice. PubMed 41092478
Evidence class is mechanistic or pharmacological.
Evidence row 307 / evidence context
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms.
mechanistic or pharmacological / very_low confidence.
Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression. PubMed 39245706
Evidence class is mechanistic or pharmacological.
Evidence row 322 / evidence context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoid treatment for autism: a proof-of-concept randomized trial. PubMed 33536055
Evidence class is mechanistic or pharmacological.
Evidence row 347 / evidence context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. PubMed 31350927
Evidence class is mechanistic or pharmacological.
Evidence row 360 / evidence context
CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. PubMed 33629929
Evidence class is mechanistic or pharmacological.
Evidence row 364 / evidence context
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
mechanistic or pharmacological / very_low confidence.
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. PubMed 21175579
Evidence class is mechanistic or pharmacological.
Evidence row 367 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. PubMed 33022751
Evidence class is mechanistic or pharmacological.
Evidence row 369 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
mechanistic or pharmacological / very_low confidence.
Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip. PubMed 40750820
Evidence class is mechanistic or pharmacological.
Evidence row 370 / evidence context
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
mechanistic or pharmacological / very_low confidence.
Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model. PubMed 40774642
Evidence class is mechanistic or pharmacological.
Evidence row 389 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
mechanistic or pharmacological / very_low confidence.
Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development. PubMed 39008349
Evidence class is mechanistic or pharmacological.
Evidence row 422 / evidence context
CBD studied for Seizure and neurodevelopmental outcomes.
mechanistic or pharmacological / very_low confidence.
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. PubMed 29540584
Evidence class is mechanistic or pharmacological.
Evidence row 431 / evidence context
CBD studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. PubMed 30585986
Evidence class is mechanistic or pharmacological.
Evidence row 465 / evidence context
THC studied for Cognition and memory.
mechanistic or pharmacological / very_low confidence.
Acute administration of THC impairs spatial but not associative memory function in zebrafish. PubMed 24639045
Evidence class is mechanistic or pharmacological.
Evidence row 511 / evidence context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. PubMed 39004335
Evidence class is mechanistic or pharmacological.
Evidence row 518 / evidence context
CBN modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish. PubMed 36424484
Evidence class is mechanistic or pharmacological.
Evidence row 522 / evidence context
CBN modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Affinity-Based Protein Profiling Reveals IDH2 as a Mitochondrial Target of Cannabinol in Receptor-Independent Neuroprotection. PubMed 40388656
Evidence class is mechanistic or pharmacological.
Evidence row 524 / evidence context
CBN modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules. PubMed 36091813
Evidence class is mechanistic or pharmacological.
Evidence row 525 / evidence context
CBN studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PubMed 41680865
Evidence class is mechanistic or pharmacological.
Evidence row 526 / evidence context
CBN studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PubMed 37764262
Evidence class is mechanistic or pharmacological.
Evidence row 527 / evidence context
CBN studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. PubMed 39275884
Evidence class is mechanistic or pharmacological.
Evidence row 528 / evidence context
CBN studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. PubMed 36228902
Evidence class is mechanistic or pharmacological.
Evidence row 531 / evidence context
CBN studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Phytocannabinoids as anti-inflammatory agents: Synergistic effects when combined with Cannabis sativa L. matrices. PubMed 41478536
Evidence class is mechanistic or pharmacological.
Evidence row 532 / evidence context
CBN studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis. PubMed 40580876
Evidence class is mechanistic or pharmacological.
Evidence row 533 / evidence context
CBN studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons. PubMed 40568800
Evidence class is mechanistic or pharmacological.
Evidence row 534 / evidence context
CBN studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. PubMed 19679411
Evidence class is mechanistic or pharmacological.
Evidence row 540 / evidence context
CBG studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PubMed 33230154
Evidence class is mechanistic or pharmacological.
Evidence row 542 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. PubMed 39596290
Evidence class is mechanistic or pharmacological.
Evidence row 547 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol. PubMed 36796712
Evidence class is mechanistic or pharmacological.
Evidence row 548 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. PubMed 40540228
Evidence class is mechanistic or pharmacological.
Evidence row 554 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Could cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study. PubMed 41548647
Evidence class is mechanistic or pharmacological.
Evidence row 556 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The impact of cannabigerol exposure on human endometrial stromal cells decidualization. PubMed 42107483
Evidence class is mechanistic or pharmacological.
Evidence row 560 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. PubMed 36272108
Evidence class is mechanistic or pharmacological.
Evidence row 561 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. PubMed 41934896
Evidence class is mechanistic or pharmacological.
Evidence row 562 / evidence context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. PubMed 35246858
Evidence class is mechanistic or pharmacological.
Evidence row 570 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. PubMed 25269802
Evidence class is mechanistic or pharmacological.
Evidence row 572 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. PubMed 40540228
Evidence class is mechanistic or pharmacological.
Evidence row 573 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. PubMed 40326034
Evidence class is mechanistic or pharmacological.
Evidence row 578 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat. PubMed 37305529
Evidence class is mechanistic or pharmacological.
Evidence row 579 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models. PubMed 41155621
Evidence class is mechanistic or pharmacological.
Evidence row 580 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation. PubMed 40706771
Evidence class is mechanistic or pharmacological.
Evidence row 581 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. PubMed 20002104
Evidence class is mechanistic or pharmacological.
Evidence row 583 / evidence context
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabigerol reverses mechanical allodynia through α2A-adrenergic modulation of thalamocortical signaling in chemotherapy-induced neuropathy. PubMed 41435878
Evidence class is mechanistic or pharmacological.
Evidence row 589 / evidence context
CBG studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. PubMed 23415610
Evidence class is mechanistic or pharmacological.
Evidence row 591 / evidence context
CBG studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. PubMed 36615835
Evidence class is mechanistic or pharmacological.
Evidence row 592 / evidence context
CBG studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation. PubMed 40818359
Evidence class is mechanistic or pharmacological.
Evidence row 594 / evidence context
CBG studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. PubMed 40725084
Evidence class is mechanistic or pharmacological.
Evidence row 595 / evidence context
CBG studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabigerol Reduces Lipid Peroxidation Influencing Oxidative Stress and Inflammation Signaling Pathways in Melanocytes Exposed to UVA Radiation. PubMed 41914282
Evidence class is mechanistic or pharmacological.
Evidence row 596 / evidence context
CBG studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabigerol Exerts In Vivo and In Vitro Anti-Inflammatory Effects via Inhibition of the MAPK and NF-κB Pathways. PubMed 41423277
Evidence class is mechanistic or pharmacological.
Evidence row 597 / evidence context
CBG studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabigerol Alleviates Liver Damage in Metabolic Dysfunction-Associated Steatohepatitis Female Mice via Inhibition of Transforming Growth Factor Beta 1. PubMed 40362835
Evidence class is mechanistic or pharmacological.
Evidence row 599 / evidence context
CBG studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Sphingolipid metabolism and insulin resistance - Does cannabigerol protect against experimental colitis induced by high-fat high-sucrose diet? PubMed 41056638
Evidence class is mechanistic or pharmacological.
Evidence row 606 / evidence context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. PubMed 39596290
Evidence class is mechanistic or pharmacological.
Evidence row 608 / evidence context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. PubMed 40725084
Evidence class is mechanistic or pharmacological.
Evidence row 610 / evidence context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. PubMed 35056807
Evidence class is mechanistic or pharmacological.
Evidence row 611 / evidence context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway. PubMed 39851511
Evidence class is mechanistic or pharmacological.
Evidence row 613 / evidence context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives. PubMed 37949940
Evidence class is mechanistic or pharmacological.
Evidence row 614 / evidence context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Skin cells protection against UVA radiation - The comparison of various antioxidants and viability tests. PubMed 39647320
Evidence class is mechanistic or pharmacological.
Evidence row 616 / evidence context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
The Anti-Inflammatory Action of Cannabigerol Accompanied by the Antioxidant Effect of 3-O-ethyl Ascorbic Acid in UVA-Irradiated Human Keratinocytes. PubMed 37652708
Evidence class is mechanistic or pharmacological.
Evidence row 617 / evidence context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells. PubMed 39357769
Evidence class is mechanistic or pharmacological.
Evidence row 619 / evidence context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. PubMed 27094344
Evidence class is mechanistic or pharmacological.
Evidence row 621 / evidence context
CBG studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PubMed 33230154
Evidence class is mechanistic or pharmacological.
Evidence row 623 / evidence context
CBG studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat. PubMed 37305529
Evidence class is mechanistic or pharmacological.
Evidence row 624 / evidence context
CBG studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Sphingolipid metabolism and insulin resistance - Does cannabigerol protect against experimental colitis induced by high-fat high-sucrose diet? PubMed 41056638
Evidence class is mechanistic or pharmacological.
Evidence row 631 / evidence context
CBG studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus. PubMed 31941059
Evidence class is mechanistic or pharmacological.
Evidence row 634 / evidence context
CBG studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. PubMed 22543671
Evidence class is mechanistic or pharmacological.
Evidence row 636 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PubMed 42163693
Evidence class is mechanistic or pharmacological.
Evidence row 651 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. PubMed 33134364
Evidence class is mechanistic or pharmacological.
Evidence row 654 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. PubMed 20619971
Evidence class is mechanistic or pharmacological.
Evidence row 655 / evidence context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots. PubMed 41668212
Evidence class is mechanistic or pharmacological.
Evidence row 662 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. PubMed 35306000
Evidence class is mechanistic or pharmacological.
Evidence row 668 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation. PubMed 40706771
Evidence class is mechanistic or pharmacological.
Evidence row 671 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabichromene is a cannabinoid CB2 receptor agonist. PubMed 31368508
Evidence class is mechanistic or pharmacological.
Evidence row 674 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy. PubMed 40790027
Evidence class is mechanistic or pharmacological.
Evidence row 675 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene. PubMed 39137108
Evidence class is mechanistic or pharmacological.
Evidence row 676 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
The Oxidation of Phytocannabinoids to Cannabinoquinoids. PubMed 32315173
Evidence class is mechanistic or pharmacological.
Evidence row 678 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Structure and Dynamics of Cannabinoid Binding to the GABAA Receptor. PubMed 40271542
Evidence class is mechanistic or pharmacological.
Evidence row 679 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. PubMed 23373571
Evidence class is mechanistic or pharmacological.
Evidence row 680 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. PubMed 22300105
Evidence class is mechanistic or pharmacological.
Evidence row 682 / evidence context
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery. PubMed 35399958
Evidence class is mechanistic or pharmacological.
Evidence row 684 / evidence context
CBC studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PubMed 41680865
Evidence class is mechanistic or pharmacological.
Evidence row 689 / evidence context
CBC studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation. PubMed 41256665
Evidence class is mechanistic or pharmacological.
Evidence row 690 / evidence context
CBC studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation. PubMed 42139799
Evidence class is mechanistic or pharmacological.
Evidence row 691 / evidence context
CBC studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PubMed 33230154
Evidence class is mechanistic or pharmacological.
Evidence row 693 / evidence context
CBC studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. PubMed 19679411
Evidence class is mechanistic or pharmacological.
Evidence row 695 / evidence context
CBC studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabichromene attenuates fracture pain but impairs bone repair in a murine tibial fracture model. PubMed 41794091
Evidence class is mechanistic or pharmacological.
Evidence row 696 / evidence context
CBC studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity. PubMed 41322279
Evidence class is mechanistic or pharmacological.
Evidence row 697 / evidence context
CBC studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain. PubMed 36551296
Evidence class is mechanistic or pharmacological.
Evidence row 699 / evidence context
CBC studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. PubMed 20942863
Evidence class is mechanistic or pharmacological.
Evidence row 700 / evidence context
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PubMed 42163693
Evidence class is mechanistic or pharmacological.
Evidence row 707 / evidence context
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. PubMed 27094344
Evidence class is mechanistic or pharmacological.
Evidence row 708 / evidence context
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. PubMed 39769302
Evidence class is mechanistic or pharmacological.
Evidence row 711 / evidence context
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. PubMed 35628241
Evidence class is mechanistic or pharmacological.
Evidence row 712 / evidence context
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties. PubMed 37242431
Evidence class is mechanistic or pharmacological.
Evidence row 713 / evidence context
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway. PubMed 36769042
Evidence class is mechanistic or pharmacological.
Evidence row 721 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
mechanistic or pharmacological / very_low confidence.
Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PubMed 41680865
Evidence class is mechanistic or pharmacological.
Evidence row 725 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
mechanistic or pharmacological / very_low confidence.
Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. PubMed 41934896
Evidence class is mechanistic or pharmacological.
Evidence row 727 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. PubMed 39769302
Evidence class is mechanistic or pharmacological.
Evidence row 728 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabichromene Induces Neuronal Differentiation in NSC-34 Cells: Insights from Transcriptomic Analysis. PubMed 36983897
Evidence class is mechanistic or pharmacological.
Evidence row 730 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations. PubMed 40358684
Evidence class is mechanistic or pharmacological.
Evidence row 732 / evidence context
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes.
mechanistic or pharmacological / very_low confidence.
The effect of cannabichromene on adult neural stem/progenitor cells. PubMed 23941747
Evidence class is mechanistic or pharmacological.
Evidence row 733 / evidence context
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PubMed 37764262
Evidence class is mechanistic or pharmacological.
Evidence row 734 / evidence context
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Tetrahydrocannabivarin (THCV) Protects Adipose-Derived Mesenchymal Stem Cells (ASC) against Endoplasmic Reticulum Stress Development and Reduces Inflammation during Adipogenesis. PubMed 37108282
Evidence class is mechanistic or pharmacological.
Evidence row 735 / evidence context
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain. PubMed 32904155
Evidence class is mechanistic or pharmacological.
Evidence row 738 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PubMed 27573936
Evidence class is mechanistic or pharmacological.
Evidence row 740 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. PubMed 42196303
Evidence class is mechanistic or pharmacological.
Evidence row 746 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption. PubMed 41947574
Evidence class is mechanistic or pharmacological.
Evidence row 751 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. PubMed 26577065
Evidence class is mechanistic or pharmacological.
Evidence row 752 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Hair Regrowth with Novel Hemp Extract: A Case Series. PubMed 37305187
Evidence class is mechanistic or pharmacological.
Evidence row 755 / evidence context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. PubMed 23712280
Evidence class is mechanistic or pharmacological.
Evidence row 761 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. PubMed 42196303
Evidence class is mechanistic or pharmacological.
Evidence row 764 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PubMed 27498155
Evidence class is mechanistic or pharmacological.
Evidence row 765 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. PubMed 21175579
Evidence class is mechanistic or pharmacological.
Evidence row 768 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. PubMed 16205722
Evidence class is mechanistic or pharmacological.
Evidence row 770 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats. PubMed 41008636
Evidence class is mechanistic or pharmacological.
Evidence row 771 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6. PubMed 30170189
Evidence class is mechanistic or pharmacological.
Evidence row 772 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. PubMed 31454413
Evidence class is mechanistic or pharmacological.
Evidence row 773 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. PubMed 20590571
Evidence class is mechanistic or pharmacological.
Evidence row 774 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. PubMed 17245367
Evidence class is mechanistic or pharmacological.
Evidence row 775 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. PubMed 23902479
Evidence class is mechanistic or pharmacological.
Evidence row 776 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. PubMed 18311186
Evidence class is mechanistic or pharmacological.
Evidence row 777 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. PubMed 25542687
Evidence class is mechanistic or pharmacological.
Evidence row 778 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site. PubMed 38691614
Evidence class is mechanistic or pharmacological.
Evidence row 779 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Loratadine, an antihistaminic drug, suppresses the proliferation of endometrial stromal cells by inhibition of TRPV2. PubMed 35714693
Evidence class is mechanistic or pharmacological.
Evidence row 780 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. PubMed 21726418
Evidence class is mechanistic or pharmacological.
Evidence row 781 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. PubMed 34500785
Evidence class is mechanistic or pharmacological.
Evidence row 782 / evidence context
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. PubMed 30074247
Evidence class is mechanistic or pharmacological.
Evidence row 783 / evidence context
THCV studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PubMed 37764262
Evidence class is mechanistic or pharmacological.
Evidence row 784 / evidence context
THCV studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PubMed 27498155
Evidence class is mechanistic or pharmacological.
Evidence row 785 / evidence context
THCV studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. PubMed 33446817
Evidence class is mechanistic or pharmacological.
Evidence row 786 / evidence context
THCV studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models. PubMed 36559009
Evidence class is mechanistic or pharmacological.
Evidence row 788 / evidence context
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
mechanistic or pharmacological / very_low confidence.
Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. PubMed 31454413
Evidence class is mechanistic or pharmacological.
Evidence row 789 / evidence context
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
mechanistic or pharmacological / very_low confidence.
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. PubMed 25542687
Evidence class is mechanistic or pharmacological.
Evidence row 791 / evidence context
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
mechanistic or pharmacological / very_low confidence.
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. PubMed 26577065
Evidence class is mechanistic or pharmacological.
Evidence row 795 / evidence context
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments. PubMed 40525419
Evidence class is mechanistic or pharmacological.
Evidence row 797 / evidence context
THCV studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PubMed 37764262
Evidence class is mechanistic or pharmacological.
Evidence row 798 / evidence context
THCV studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PubMed 33230154
Evidence class is mechanistic or pharmacological.
Evidence row 799 / evidence context
THCV studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. PubMed 19679411
Evidence class is mechanistic or pharmacological.
Evidence row 801 / evidence context
THCV studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. PubMed 20590571
Evidence class is mechanistic or pharmacological.
Evidence row 802 / evidence context
THCV studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. PubMed 17245367
Evidence class is mechanistic or pharmacological.
Evidence row 803 / evidence context
THCV studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans. PubMed 41135090
Evidence class is mechanistic or pharmacological.
Evidence row 809 / evidence context
HHC modulates CB1.
mechanistic or pharmacological / very_low confidence.
Crystal structures of agonist-bound human cannabinoid receptor CB1. PubMed 40866700
Evidence class is mechanistic or pharmacological.
Evidence row 810 / evidence context
THC modulates CB1.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. PubMed 35489334
Evidence class is mechanistic or pharmacological.
Evidence row 811 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism. PubMed 38101408
Evidence class is mechanistic or pharmacological.
Evidence row 812 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
A cryptic pocket in CB1 drives peripheral and functional selectivity. PubMed 40044849
Evidence class is mechanistic or pharmacological.
Evidence row 815 / evidence context
Endocannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Assay of CB1 Receptor Binding. PubMed 27245890
Evidence class is mechanistic or pharmacological.
Evidence row 816 / evidence context
THC modulates CB1.
mechanistic or pharmacological / very_low confidence.
Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1. PubMed 38830102
Evidence class is mechanistic or pharmacological.
Evidence row 822 / evidence context
THC modulates CB1.
mechanistic or pharmacological / very_low confidence.
Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. PubMed 22343625
Evidence class is mechanistic or pharmacological.
Evidence row 823 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity. PubMed 38675703
Evidence class is mechanistic or pharmacological.
Evidence row 824 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Allosteric modulation of the cannabinoid CB1 receptor. PubMed 16113085
Evidence class is mechanistic or pharmacological.
Evidence row 825 / evidence context
THC modulates CB1.
mechanistic or pharmacological / very_low confidence.
Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation. PubMed 31968549
Evidence class is mechanistic or pharmacological.
Evidence row 826 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. PubMed 28103441
Evidence class is mechanistic or pharmacological.
Evidence row 828 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
The future of type 1 cannabinoid receptor allosteric ligands. PubMed 29355038
Evidence class is mechanistic or pharmacological.
Evidence row 829 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). PubMed 25162172
Evidence class is mechanistic or pharmacological.
Evidence row 830 / evidence context
HHC modulates CB1.
mechanistic or pharmacological / very_low confidence.
Crystal structures of agonist-bound human cannabinoid receptor CB1. PubMed 28678776
Evidence class is mechanistic or pharmacological.
Evidence row 834 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Structural mechanism of CB1R binding to peripheral and biased inverse agonists. PubMed 39695122
Evidence class is mechanistic or pharmacological.
Evidence row 835 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Targeting mechanosensitive cannabinoid receptor 1 with isoflavone prodrugs attenuates atherosclerotic endothelial dysfunction. PubMed 41559687
Evidence class is mechanistic or pharmacological.
Evidence row 836 / evidence context
Endocannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist. PubMed 40521518
Evidence class is mechanistic or pharmacological.
Evidence row 844 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. PubMed 17895407
Evidence class is mechanistic or pharmacological.
Evidence row 851 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism. PubMed 36088492
Evidence class is mechanistic or pharmacological.
Evidence row 852 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Role of the cannabinoid CB1 receptor in methamphetamine-induced social and recognition memory impairment. PubMed 35429587
Evidence class is mechanistic or pharmacological.
Evidence row 853 / evidence context
Endocannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models. PubMed 40855505
Evidence class is mechanistic or pharmacological.
Evidence row 854 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Adipocyte cannabinoid CB1 receptor deficiency alleviates high fat diet-induced memory deficit, depressive-like behavior, neuroinflammation and impairment in adult neurogenesis. PubMed 31491589
Evidence class is mechanistic or pharmacological.
Evidence row 856 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
A cannabinoid link between mitochondria and memory. PubMed 27828947
Evidence class is mechanistic or pharmacological.
Evidence row 857 / evidence context
Endocannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome. PubMed 39300547
Evidence class is mechanistic or pharmacological.
Evidence row 859 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Cross state-dependent memory retrieval between cannabinoid CB1 and serotonergic 5-HT1A receptor agonists in the mouse dorsal hippocampus. PubMed 35595026
Evidence class is mechanistic or pharmacological.
Evidence row 860 / evidence context
Cannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Adenosine receptors are the on-and-off switch of astrocytic cannabinoid type 1 (CB1) receptor effect upon synaptic plasticity in the medial prefrontal cortex. PubMed 38482984
Evidence class is mechanistic or pharmacological.
Evidence row 861 / evidence context
Endocannabinoids modulates CB1.
mechanistic or pharmacological / very_low confidence.
Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice. PubMed 36613469
Evidence class is mechanistic or pharmacological.
Evidence row 867 / evidence context
THC modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabichromene is a cannabinoid CB2 receptor agonist. PubMed 31368508
Evidence class is mechanistic or pharmacological.
Evidence row 871 / evidence context
THC modulates CB2.
mechanistic or pharmacological / very_low confidence.
A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay. PubMed 40271066
Evidence class is mechanistic or pharmacological.
Evidence row 874 / evidence context
THC modulates CB2.
mechanistic or pharmacological / very_low confidence.
CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. PubMed 26124120
Evidence class is mechanistic or pharmacological.
Evidence row 876 / evidence context
Endocannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Crystal Structure of the Human Cannabinoid Receptor CB2. PubMed 30639103
Evidence class is mechanistic or pharmacological.
Evidence row 877 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex. PubMed 32004460
Evidence class is mechanistic or pharmacological.
Evidence row 878 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. PubMed 28220706
Evidence class is mechanistic or pharmacological.
Evidence row 879 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
A Cannabinoid Type 2 (CB2) Receptor Agonist Augments NOS-Dependent Responses of Cerebral Arterioles During Type 1 Diabetes. PubMed 36889269
Evidence class is mechanistic or pharmacological.
Evidence row 880 / evidence context
Endocannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder. PubMed 33749323
Evidence class is mechanistic or pharmacological.
Evidence row 881 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
CB2 cannabinoid receptor-mediated peripheral antinociception. PubMed 11514083
Evidence class is mechanistic or pharmacological.
Evidence row 883 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
CB2 cannabinoid receptor mediation of antinociception. PubMed 16563625
Evidence class is mechanistic or pharmacological.
Evidence row 884 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
The Cannabinoid-2 receptor agonist, 1-phenylisatin, protects against cisplatin-induced nephrotoxicity in mice. PubMed 36058263
Evidence class is mechanistic or pharmacological.
Evidence row 885 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid Receptor Type 2 Agonist Reduces Morphine Tolerance via Mitogen Activated Protein Kinase Phosphatase Induction and Mitogen Activated Protein Kinase Dephosphorylation. PubMed 34774714
Evidence class is mechanistic or pharmacological.
Evidence row 886 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats. PubMed 27608434
Evidence class is mechanistic or pharmacological.
Evidence row 887 / evidence context
THC modulates CB2.
mechanistic or pharmacological / very_low confidence.
The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. PubMed 20849866
Evidence class is mechanistic or pharmacological.
Evidence row 888 / evidence context
Endocannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Structural basis of selective cannabinoid CB2 receptor activation. PubMed 36922494
Evidence class is mechanistic or pharmacological.
Evidence row 895 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy. PubMed 39334169
Evidence class is mechanistic or pharmacological.
Evidence row 897 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease. PubMed 38662453
Evidence class is mechanistic or pharmacological.
Evidence row 899 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation. PubMed 39173999
Evidence class is mechanistic or pharmacological.
Evidence row 901 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation. PubMed 36475439
Evidence class is mechanistic or pharmacological.
Evidence row 902 / evidence context
Endocannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice. PubMed 37061199
Evidence class is mechanistic or pharmacological.
Evidence row 903 / evidence context
Endocannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. PubMed 18615177
Evidence class is mechanistic or pharmacological.
Evidence row 904 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice. PubMed 30666359
Evidence class is mechanistic or pharmacological.
Evidence row 906 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain. PubMed 37286073
Evidence class is mechanistic or pharmacological.
Evidence row 907 / evidence context
THC modulates CB2.
mechanistic or pharmacological / very_low confidence.
Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2. PubMed 26824325
Evidence class is mechanistic or pharmacological.
Evidence row 908 / evidence context
Endocannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. PubMed 23960212
Evidence class is mechanistic or pharmacological.
Evidence row 909 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive Microglia In Vitro. PubMed 38751621
Evidence class is mechanistic or pharmacological.
Evidence row 911 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. PubMed 12823482
Evidence class is mechanistic or pharmacological.
Evidence row 912 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats. PubMed 30414958
Evidence class is mechanistic or pharmacological.
Evidence row 913 / evidence context
THC modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation. PubMed 36583304
Evidence class is mechanistic or pharmacological.
Evidence row 914 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling. PubMed 41875735
Evidence class is mechanistic or pharmacological.
Evidence row 915 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease. PubMed 40332343
Evidence class is mechanistic or pharmacological.
Evidence row 916 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy. PubMed 41383775
Evidence class is mechanistic or pharmacological.
Evidence row 918 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases. PubMed 40791361
Evidence class is mechanistic or pharmacological.
Evidence row 920 / evidence context
2-AG modulates CB2.
mechanistic or pharmacological / very_low confidence.
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. PubMed 16086683
Evidence class is mechanistic or pharmacological.
Evidence row 921 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor 2 affect the inflammatory response in periodontitis by regulating macrophage M1/M2 polarization. PubMed 41310604
Evidence class is mechanistic or pharmacological.
Evidence row 922 / evidence context
THC modulates CB2.
mechanistic or pharmacological / very_low confidence.
The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. PubMed 18247131
Evidence class is mechanistic or pharmacological.
Evidence row 924 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor type 2 agonist GP1a attenuates macrophage activation induced by M. bovis-BCG by inhibiting NF-κB signaling. PubMed 39538989
Evidence class is mechanistic or pharmacological.
Evidence row 925 / evidence context
Cannabinoids modulates CB2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases. PubMed 41740200
Evidence class is mechanistic or pharmacological.
Evidence row 931 / evidence context
Endocannabinoids modulates GPR55.
mechanistic or pharmacological / very_low confidence.
The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. PubMed 18757503
Evidence class is mechanistic or pharmacological.
Evidence row 936 / evidence context
CBD modulates GPR55.
mechanistic or pharmacological / very_low confidence.
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. PubMed 17704827
Evidence class is mechanistic or pharmacological.
Evidence row 940 / evidence context
CBD modulates GPR55.
mechanistic or pharmacological / very_low confidence.
The orphan receptor GPR55 is a novel cannabinoid receptor. PubMed 17876302
Evidence class is mechanistic or pharmacological.
Evidence row 943 / evidence context
CBD modulates GPR55.
mechanistic or pharmacological / very_low confidence.
Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors. PubMed 36016551
Evidence class is mechanistic or pharmacological.
Evidence row 946 / evidence context
THC modulates GPR18.
mechanistic or pharmacological / very_low confidence.
Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18. PubMed 32365486
Evidence class is mechanistic or pharmacological.
Evidence row 949 / evidence context
THC modulates GPR18.
mechanistic or pharmacological / very_low confidence.
Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18. PubMed 29902723
Evidence class is mechanistic or pharmacological.
Evidence row 950 / evidence context
THC modulates GPR18.
mechanistic or pharmacological / very_low confidence.
Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. PubMed 24762058
Evidence class is mechanistic or pharmacological.
Evidence row 951 / evidence context
Cannabinoids modulates GPR18.
mechanistic or pharmacological / very_low confidence.
Structural insights into the activation of G protein-coupled receptor 119 by the agonist GSK1292263 and ligands selectivity among novel cannabinoid receptors. PubMed 40562148
Evidence class is mechanistic or pharmacological.
Evidence row 953 / evidence context
Endocannabinoids modulates GPR18.
mechanistic or pharmacological / very_low confidence.
GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine. PubMed 27018161
Evidence class is mechanistic or pharmacological.
Evidence row 954 / evidence context
Endocannabinoids modulates GPR18.
mechanistic or pharmacological / very_low confidence.
Protective Effect of N-Arachidonoyl Glycine-GPR18 Signaling after Excitotoxical Lesion in Murine Organotypic Hippocampal Slice Cultures. PubMed 30871175
Evidence class is mechanistic or pharmacological.
Evidence row 955 / evidence context
CBD modulates GPR18.
mechanistic or pharmacological / very_low confidence.
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. PubMed 20346144
Evidence class is mechanistic or pharmacological.
Evidence row 956 / evidence context
CBD modulates GPR18.
mechanistic or pharmacological / very_low confidence.
siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration. PubMed 22834922
Evidence class is mechanistic or pharmacological.
Evidence row 957 / evidence context
THC modulates GPR18.
mechanistic or pharmacological / very_low confidence.
Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. PubMed 21595653
Evidence class is mechanistic or pharmacological.
Evidence row 959 / evidence context
CBD modulates GPR18.
mechanistic or pharmacological / very_low confidence.
A GPR18-based signalling system regulates IOP in murine eye. PubMed 23461720
Evidence class is mechanistic or pharmacological.
Evidence row 960 / evidence context
CBD modulates GPR18.
mechanistic or pharmacological / very_low confidence.
The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure. PubMed 24431468
Evidence class is mechanistic or pharmacological.
Evidence row 962 / evidence context
CBD modulates GPR18.
mechanistic or pharmacological / very_low confidence.
Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature. PubMed 24751709
Evidence class is mechanistic or pharmacological.
Evidence row 967 / evidence context
Endocannabinoids modulates GPR119.
mechanistic or pharmacological / very_low confidence.
Regulation of GPR119 receptor activity with endocannabinoid-like lipids. PubMed 23074242
Evidence class is mechanistic or pharmacological.
Evidence row 978 / evidence context
CBD modulates TRPV1.
mechanistic or pharmacological / very_low confidence.
Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. PubMed 37199723
Evidence class is mechanistic or pharmacological.
Evidence row 982 / evidence context
Endocannabinoids modulates TRPV1.
mechanistic or pharmacological / very_low confidence.
The TRPV1 channel regulates glucose metabolism. PubMed 31408376
Evidence class is mechanistic or pharmacological.
Evidence row 991 / evidence context
CBD modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. PubMed 37199723
Evidence class is mechanistic or pharmacological.
Evidence row 992 / evidence context
CBD modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
Tyrosine phosphorylation and palmitoylation of TRPV2 ion channel tune microglial beta-amyloid peptide phagocytosis. PubMed 39227967
Evidence class is mechanistic or pharmacological.
Evidence row 993 / evidence context
CBD modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
Cannabinoid non-cannabidiol site modulation of TRPV2 structure and function. PubMed 36470868
Evidence class is mechanistic or pharmacological.
Evidence row 994 / evidence context
CBD modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
Molecular mechanism of TRPV2 channel modulation by cannabidiol. PubMed 31566564
Evidence class is mechanistic or pharmacological.
Evidence row 998 / evidence context
CBD modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
TRPV2, a novel player in the human ovary and human granulosa cells. PubMed 37610352
Evidence class is mechanistic or pharmacological.
Evidence row 999 / evidence context
THC modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
The Protective Effect of CBD in a Model of In Vitro Ischemia May Be Mediated by Agonism on TRPV2 Channel and Microglia Activation. PubMed 36292998
Evidence class is mechanistic or pharmacological.
Evidence row 1000 / evidence context
CBD modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib. PubMed 34971020
Evidence class is mechanistic or pharmacological.
Evidence row 1001 / evidence context
CBD modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. PubMed 36747846
Evidence class is mechanistic or pharmacological.
Evidence row 1002 / evidence context
CBD modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. PubMed 23079154
Evidence class is mechanistic or pharmacological.
Evidence row 1003 / evidence context
CBD modulates TRPV2.
mechanistic or pharmacological / very_low confidence.
Cannabidiol Enhances Microglial Beta-Amyloid Peptide Phagocytosis and Clearance via Vanilloid Family Type 2 Channel Activation. PubMed 35628181
Evidence class is mechanistic or pharmacological.
Evidence row 1006 / evidence context
THCV modulates TRPV3.
mechanistic or pharmacological / very_low confidence.
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PubMed 27498155
Evidence class is mechanistic or pharmacological.
Evidence row 1007 / evidence context
THCV modulates TRPV3.
mechanistic or pharmacological / very_low confidence.
TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site. PubMed 38691614
Evidence class is mechanistic or pharmacological.
Evidence row 1008 / evidence context
THC modulates TRPV3.
mechanistic or pharmacological / very_low confidence.
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. PubMed 21726418
Evidence class is mechanistic or pharmacological.
Evidence row 1009 / evidence context
CBD modulates TRPV3.
mechanistic or pharmacological / very_low confidence.
Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. PubMed 37199723
Evidence class is mechanistic or pharmacological.
Evidence row 1010 / evidence context
CBD modulates TRPV3.
mechanistic or pharmacological / very_low confidence.
Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. PubMed 36747846
Evidence class is mechanistic or pharmacological.
Evidence row 1012 / evidence context
CBD modulates TRPV3.
mechanistic or pharmacological / very_low confidence.
Human podocytes express functional thermosensitive TRPV channels. PubMed 28945920
Evidence class is mechanistic or pharmacological.
Evidence row 1013 / evidence context
CBD modulates TRPV3.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol-TRPV3 Mediated Biological Activities-Findings From Molecular Docking, Simulation and Proteins Network Interactions. PubMed 40025806
Evidence class is mechanistic or pharmacological.
Evidence row 1015 / evidence context
THC modulates TRPV3.
mechanistic or pharmacological / very_low confidence.
The Impact of a Quinone Scaffold on Thermo-TRPs Modulation by Dimethylheptyl Phytocannabinoids. PubMed 40141324
Evidence class is mechanistic or pharmacological.
Evidence row 1018 / evidence context
CBD modulates TRPV4.
mechanistic or pharmacological / very_low confidence.
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. PubMed 33629929
Evidence class is mechanistic or pharmacological.
Evidence row 1019 / evidence context
THC modulates TRPV4.
mechanistic or pharmacological / very_low confidence.
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. PubMed 21726418
Evidence class is mechanistic or pharmacological.
Evidence row 1021 / evidence context
CBD modulates TRPV4.
mechanistic or pharmacological / very_low confidence.
Human podocytes express functional thermosensitive TRPV channels. PubMed 28945920
Evidence class is mechanistic or pharmacological.
Evidence row 1022 / evidence context
Cannabinoids modulates TRPV4.
mechanistic or pharmacological / very_low confidence.
Modification of TRPV4 activity by acetaminophen. PubMed 32051870
Evidence class is mechanistic or pharmacological.
Evidence row 1023 / evidence context
Endocannabinoids modulates TRPV4.
mechanistic or pharmacological / very_low confidence.
Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region. PubMed 38750093
Evidence class is mechanistic or pharmacological.
Evidence row 1026 / evidence context
Cannabinoids modulates TRPV4.
mechanistic or pharmacological / very_low confidence.
Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy. PubMed 41802611
Evidence class is mechanistic or pharmacological.
Evidence row 1027 / evidence context
Endocannabinoids modulates TRPV4.
mechanistic or pharmacological / very_low confidence.
Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol. PubMed 26294342
Evidence class is mechanistic or pharmacological.
Evidence row 1028 / evidence context
CBD modulates TRPV4.
mechanistic or pharmacological / very_low confidence.
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. PubMed 25061872
Evidence class is mechanistic or pharmacological.
Evidence row 1035 / evidence context
Cannabinoids modulates TRPA1.
mechanistic or pharmacological / very_low confidence.
Modification of TRPV4 activity by acetaminophen. PubMed 32051870
Evidence class is mechanistic or pharmacological.
Evidence row 1037 / evidence context
THC modulates TRPA1.
mechanistic or pharmacological / very_low confidence.
Identification of the TRPA1 cannabinoid-binding site. PubMed 39368566
Evidence class is mechanistic or pharmacological.
Evidence row 1038 / evidence context
Cannabinoids modulates TRPA1.
mechanistic or pharmacological / very_low confidence.
Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation. PubMed 38219731
Evidence class is mechanistic or pharmacological.
Evidence row 1041 / evidence context
Endocannabinoids modulates TRPA1.
mechanistic or pharmacological / very_low confidence.
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. PubMed 25065940
Evidence class is mechanistic or pharmacological.
Evidence row 1042 / evidence context
Cannabinoids modulates TRPA1.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons. PubMed 21645531
Evidence class is mechanistic or pharmacological.
Evidence row 1043 / evidence context
CBD modulates TRPA1.
mechanistic or pharmacological / very_low confidence.
Cannabidiol activation of vagal afferent neurons requires TRPA1. PubMed 32965166
Evidence class is mechanistic or pharmacological.
Evidence row 1046 / evidence context
CBD modulates TRPA1.
mechanistic or pharmacological / very_low confidence.
Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. PubMed 32873774
Evidence class is mechanistic or pharmacological.
Evidence row 1047 / evidence context
CBD modulates TRPA1.
mechanistic or pharmacological / very_low confidence.
Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV. PubMed 38408345
Evidence class is mechanistic or pharmacological.
Evidence row 1049 / evidence context
THC modulates TRPM8.
mechanistic or pharmacological / very_low confidence.
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. PubMed 18354058
Evidence class is mechanistic or pharmacological.
Evidence row 1050 / evidence context
THC modulates TRPM8.
mechanistic or pharmacological / very_low confidence.
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. PubMed 21175579
Evidence class is mechanistic or pharmacological.
Evidence row 1051 / evidence context
CBG modulates TRPM8.
mechanistic or pharmacological / very_low confidence.
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. PubMed 25269802
Evidence class is mechanistic or pharmacological.
Evidence row 1052 / evidence context
CBG modulates TRPM8.
mechanistic or pharmacological / very_low confidence.
Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. PubMed 40540228
Evidence class is mechanistic or pharmacological.
Evidence row 1058 / evidence context
CBD modulates TRPM8.
mechanistic or pharmacological / very_low confidence.
Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV. PubMed 38408345
Evidence class is mechanistic or pharmacological.
Evidence row 1059 / evidence context
Endocannabinoids modulates TRPM8.
mechanistic or pharmacological / very_low confidence.
TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice. PubMed 39684707
Evidence class is mechanistic or pharmacological.
Evidence row 1061 / evidence context
Endocannabinoids modulates TRPM8.
mechanistic or pharmacological / very_low confidence.
Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. PubMed 17428469
Evidence class is mechanistic or pharmacological.
Evidence row 1062 / evidence context
CBG modulates TRPM8.
mechanistic or pharmacological / very_low confidence.
Iodine-mediated cyclization of cannabigerol (CBG) expands the cannabinoid biological and chemical space. PubMed 30077611
Evidence class is mechanistic or pharmacological.
Evidence row 1067 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells. PubMed 34126378
Evidence class is mechanistic or pharmacological.
Evidence row 1071 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Endocannabinoids. PubMed 35038882
Evidence class is mechanistic or pharmacological.
Evidence row 1072 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabinoid CB1 receptors regulate salivation. PubMed 35986066
Evidence class is mechanistic or pharmacological.
Evidence row 1073 / evidence context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. PubMed 11470906
Evidence class is mechanistic or pharmacological.
Evidence row 1084 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. PubMed 39612328
Evidence class is mechanistic or pharmacological.
Evidence row 1085 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. PubMed 24768821
Evidence class is mechanistic or pharmacological.
Evidence row 1087 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice. PubMed 36125319
Evidence class is mechanistic or pharmacological.
Evidence row 1088 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. PubMed 33450278
Evidence class is mechanistic or pharmacological.
Evidence row 1089 / evidence context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b. PubMed 36481187
Evidence class is mechanistic or pharmacological.
Evidence row 1097 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. PubMed 17449181
Evidence class is mechanistic or pharmacological.
Evidence row 1101 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice. PubMed 29936173
Evidence class is mechanistic or pharmacological.
Evidence row 1102 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
GPR119 Is a Potent Regulator of Human Sebocyte Biology. PubMed 32142797
Evidence class is mechanistic or pharmacological.
Evidence row 1103 / evidence context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy. PubMed 30702457
Evidence class is mechanistic or pharmacological.
Evidence row 1106 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. PubMed 35176443
Evidence class is mechanistic or pharmacological.
Evidence row 1109 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation. PubMed 40563990
Evidence class is mechanistic or pharmacological.
Evidence row 1110 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Probiotics and palmitoylethanolamide (PEA) for osteoarthritic pain: individual effects in a multiple baseline design study. PubMed 41709243
Evidence class is mechanistic or pharmacological.
Evidence row 1113 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Protective effect of palmitoylethanolamide in a rat model of cystitis. PubMed 25463999
Evidence class is mechanistic or pharmacological.
Evidence row 1117 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. PubMed 27720681
Evidence class is mechanistic or pharmacological.
Evidence row 1118 / evidence context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. PubMed 28336953
Evidence class is mechanistic or pharmacological.
Evidence row 1125 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. PubMed 9344854
Evidence class is mechanistic or pharmacological.
Evidence row 1128 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. PubMed 10221757
Evidence class is mechanistic or pharmacological.
Evidence row 1129 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. PubMed 8900284
Evidence class is mechanistic or pharmacological.
Evidence row 1130 / evidence context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist. PubMed 10574567
Evidence class is mechanistic or pharmacological.
Evidence row 1132 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. PubMed 15245490
Evidence class is mechanistic or pharmacological.
Evidence row 1133 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. PubMed 17459108
Evidence class is mechanistic or pharmacological.
Evidence row 1134 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. PubMed 24644287
Evidence class is mechanistic or pharmacological.
Evidence row 1135 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Endovanilloids are potential activators of the trigeminovascular nocisensor complex. PubMed 27189587
Evidence class is mechanistic or pharmacological.
Evidence row 1136 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population. PubMed 20354008
Evidence class is mechanistic or pharmacological.
Evidence row 1137 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. PubMed 15289293
Evidence class is mechanistic or pharmacological.
Evidence row 1138 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. PubMed 15006899
Evidence class is mechanistic or pharmacological.
Evidence row 1139 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells. PubMed 25995819
Evidence class is mechanistic or pharmacological.
Evidence row 1140 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1. PubMed 28701511
Evidence class is mechanistic or pharmacological.
Evidence row 1141 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. PubMed 16760924
Evidence class is mechanistic or pharmacological.
Evidence row 1142 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. PubMed 33568652
Evidence class is mechanistic or pharmacological.
Evidence row 1143 / evidence context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. PubMed 17984664
Evidence class is mechanistic or pharmacological.
Evidence row 1145 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. PubMed 11259648
Evidence class is mechanistic or pharmacological.
Evidence row 1147 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. PubMed 17698254
Evidence class is mechanistic or pharmacological.
Evidence row 1148 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. PubMed 16639008
Evidence class is mechanistic or pharmacological.
Evidence row 1149 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. PubMed 12787057
Evidence class is mechanistic or pharmacological.
Evidence row 1150 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. PubMed 15901805
Evidence class is mechanistic or pharmacological.
Evidence row 1151 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Activation of CB1R alleviates central sensitization by regulating HCN2-pNR2B signaling in a chronic migraine rat model. PubMed 37085778
Evidence class is mechanistic or pharmacological.
Evidence row 1152 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor. PubMed 15148262
Evidence class is mechanistic or pharmacological.
Evidence row 1153 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats. PubMed 22309979
Evidence class is mechanistic or pharmacological.
Evidence row 1155 / evidence context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. PubMed 12356827
Evidence class is mechanistic or pharmacological.
Evidence row 1159 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. PubMed 18806815
Evidence class is mechanistic or pharmacological.
Evidence row 1160 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. PubMed 12023533
Evidence class is mechanistic or pharmacological.
Evidence row 1161 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. PubMed 22454039
Evidence class is mechanistic or pharmacological.
Evidence row 1162 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria. PubMed 32696508
Evidence class is mechanistic or pharmacological.
Evidence row 1163 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. PubMed 15233865
Evidence class is mechanistic or pharmacological.
Evidence row 1164 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B. PubMed 29958841
Evidence class is mechanistic or pharmacological.
Evidence row 1165 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Mechanism of platelet activation induced by endocannabinoids in blood and plasma. PubMed 23789792
Evidence class is mechanistic or pharmacological.
Evidence row 1166 / evidence context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
(Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells. PubMed 19255745
Evidence class is mechanistic or pharmacological.
Evidence row 1168 / evidence context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. PubMed 27809877
Evidence class is mechanistic or pharmacological.
Evidence row 1169 / evidence context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. PubMed 23570577
Evidence class is mechanistic or pharmacological.
Evidence row 1170 / evidence context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function. PubMed 27759003
Evidence class is mechanistic or pharmacological.
Evidence row 1177 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study. PubMed 35203453
Evidence class is mechanistic or pharmacological.
Evidence row 1179 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine. PubMed 21573043
Evidence class is mechanistic or pharmacological.
Evidence row 1183 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease. PubMed 26707833
Evidence class is mechanistic or pharmacological.
Evidence row 1184 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. PubMed 16081411
Evidence class is mechanistic or pharmacological.
Evidence row 1185 / evidence context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. PubMed 17574742
Evidence class is mechanistic or pharmacological.
Evidence row 1189 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. PubMed 12010121
Evidence class is mechanistic or pharmacological.
Evidence row 1190 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PubMed 22125609
Evidence class is mechanistic or pharmacological.
Evidence row 1191 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. PubMed 23707281
Evidence class is mechanistic or pharmacological.
Evidence row 1193 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
High levels of endogenous lipid mediators (N-acylethanolamines) in women with chronic widespread pain during acute tissue trauma. PubMed 27531672
Evidence class is mechanistic or pharmacological.
Evidence row 1200 / evidence context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. PubMed 16154384
Evidence class is mechanistic or pharmacological.
Source-Backed Connections
Related pages in the current encyclopedia
target
CB1
339 evidence rows / 255 sources
target
CB2
269 evidence rows / 196 sources
target
TRPV1
144 evidence rows / 96 sources
target
TRPA1
65 evidence rows / 37 sources
target
TRPM8
61 evidence rows / 28 sources
target
GPR55
59 evidence rows / 47 sources
target
TRPV2
58 evidence rows / 30 sources
target
FAAH
57 evidence rows / 50 sources
Nearby Terms